Mori Hiroyoshi, Otsuka Fumiyuki, Gupta Anuj, Jinnouchi Hiroyuki, Torii Sho, Harari Emanuel, Virmani Renu, Finn Aloke V
a Department of Pathology , CVPath Institute , Gaithersburg , MD , USA.
b Department of Cardiology , University of Maryland, School of Medicine , Baltimore , MD , USA.
Expert Rev Cardiovasc Ther. 2017 Nov;15(11):835-846. doi: 10.1080/14779072.2017.1386098. Epub 2017 Oct 8.
Polymers are an essential component of drug-eluting stents (DES) used to control drug release but remain the most controversial component of DES technology. There are two types of polymers employed in DES: durable polymer based DES (DP-DES) and biodegradable polymer DES (BP-DES). First-generation DES were exclusively composed of DP and demonstrated increased rates of late stent failure due in part to poor polymer biocompatibility. Newer generations DES use more biocompatible durable polymers or biodegradable polymers. Areas covered: We will cover issues identified with 1st-generation DP-DES, areas of success and failure in 2nd-generation DP-DES and examine the promise and shortcomings of BP-DES. Briefly, fluorinated polymers used in 2nd-generation DP-DES have excellent anti-thrombogenicity and better biocompatibility than 1st-generation DES polymers. However, these devices lead to persistent drug exposure to the endothelium which impairs endothelial function and predisposes towards neoatherosclerosis. Meanwhile, BP-DES has shortened the duration of drug exposure which might be beneficial for endothelial functional recovery leading to less neoatherosclerosis. However, it remains uncertain whether the long-term biocompatibility of bare metal surfaces is better than that of polymer-coated metals. Expert commentary: Each technology has distinct advantages, which can be optimized depending upon the particular characteristics of the patient being treated.
